December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Vivek Subbiah: From novel diagnostics to cutting-edge therapies like Leptomeningeal Metastatic Disease
Dec 11, 2024, 08:39

Vivek Subbiah: From novel diagnostics to cutting-edge therapies like Leptomeningeal Metastatic Disease

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:

“Hot off the press, Nature Reviews Clinical Oncology.

Leptomeningeal Metastatic Disease: New Frontiers and Future Directions – Discover groundbreaking insights into LMD in our latest review.

From novel diagnostics to cutting-edge therapies like intrathecal and immunotherapies, we explore the path forward in tackling this challenging condition.

With advances in mechanistic science and trial design, there’s hope on the horizon for improving patient outcomes.

Kudos to Ahmad Ozair, Alireza Mansouri, Manmeet Ahluwalia for spearheading this work!!!

Many thanks to all co-authors:

Debarati Bhanja, Arjun Sahgal, Mustafa Khasraw, Chetan Bettegowda, Graeme Woodworth et. al.

Leptomeningeal metastatic disease: new frontiers and future directions.

Authors: Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz, Stuart A. Grossman, Arjun Sahgal, Emilie Le Rhun, Michael Weller, Tobias Weiss, Tracy T. Batchelor, Patrick Y. Wen, Daphne A. Haas-Kogan, Mustafa Khasraw, Roberta Rudà, Riccardo Soffietti, Philipp Vollmuth, Vivek Subbiah, Chetan Bettegowda, Lily C. Pham, Graeme F. Woodworth, Manmeet S. Ahluwalia and Alireza Mansouri.

Vivek Subbiah: From novel diagnostics to cutting-edge therapies like Leptomeningeal Metastatic Disease

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.